Antitumor Activity of TAK-285, an Investigational, Non-Pgp Substrate HER2/EGFR Kinase Inhibitor, in Cultured Tumor Cells, Mouse and Rat Xenograft Tumors, and in an HER2-Positive Brain Metastasis Model

Breast cancer therapy has improved following the development of drugs with specific molecular targets, exemplified by inhibitors of human epidermal growth factor receptor-2 (HER2) or epidermal growth factor receptor (EGFR) such as trastuzumab and lapatinib. However, these drugs have little effect on...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Akiko, Takagi, Shinji, Yusa, Tadashi, Yaguchi, Masahiro, Hayashi, Akira, Tamura, Toshiya, Kawakita, Youichi, Ishikawa, Tomoyasu, Ohta, Yoshikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753530/
https://www.ncbi.nlm.nih.gov/pubmed/23983820
http://dx.doi.org/10.7150/jca.6689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753530/
https://www.ncbi.nlm.nih.gov/pubmed/23983820
http://dx.doi.org/10.7150/jca.6689

Ejemplares similares